Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials

被引：0

作者：

Blauvelt, Andrew ^{[11
]}

Armstrong, April ^{[1
]}

Merola, Joseph F. ^{[2
]}

Strober, Bruce ^{[3
,4
,5
]}

de Cuyper, Dirk ^{[6
]}

Peterson, Luke ^{[7
]}

Davies, Owen ^{[8
]}

Stark, Jeffrey L. ^{[9
]}

Lebwohl, Mark ^{[10
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR USA

[2] Univ Calif Los Angeles UCLA, Los Angeles, CA USA

[3] UT Southwestern Med Ctr, Div Rheumatol, Dept Dermatol, Dallas, TX USA

[4] UT Southwestern Med Ctr, Dept Med, Div Rheumatol, Dallas, TX USA

[5] Yale Univ, Dept Dermatol, New Haven, CT USA

[6] Cent Connecticut Dermatol Res, Cromwell, CT USA

[7] UCB Pharm, Brussels, Belgium

[8] UCB Pharm, Morrisville, NC USA

[9] UCB Pharm, Slough, England

[10] UCB Pharm, Smyrna, GA USA

[11] Icahn Sch Med Mt Sinai, Dept Dermatol, New York, NY USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2024年 / 91卷 / 01期

关键词：

bimekizumab; clinical trial; depression; eC-SSRS; long-term; mental health; PHQ-9; plaque; SEVERE PLAQUE PSORIASIS; DOUBLE-BLIND; MULTICENTER; BRODALUMAB; DEPRESSION; USTEKINUMAB; SUICIDALITY; EFFICACY; VALIDITY; ANXIETY;

D O I：

10.1016/j.jaad.2024.02.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Patients with psoriasis have increased risk of suicidal ideation and behavior (SIB) and depression. Bimekizumab, a biologic that inhibits interleukin (IL)-17A and IL-17F, received Food and Drug Administration approval in 2023 for moderate to severe plaque psoriasis, following 2021 European Medicines Agency approval. Objective: To report SIB and depression in patients with moderate to severe psoriasis treated in bimekizumab clinical trials. Methods: Mental health changes, including neuropsychiatric events, were actively monitored across 9 bimekizumab clinical trials in psoriasis phase 2/3 trials. The patient-reported electronic Columbia-Suicide Severity Rating Scale (measuring SIB) and Patient Health Questionnaire-9 (measuring depression) were administered, monitored by an independent Neuropsychiatric Adjudication Committee. Results: Throughout 7166 patient-years (PY) of bimekizumab exposure, the adjudicated SIB rate was 0.13/ 100PY; SIB ranges for the general psoriasis population and patients receiving anti-IL-17A/anti-IL-23

引用

页码：72 / 81

页数：10

共 50 条

[41] Incidence of serious gastrointestinal events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Data from 3 randomized clinical trials
Gooderham, M.
Elewski, B.
Pariser, D.
Sofen, H.
Mendelsohn, A.
Li, Q.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 63 - 63
[42] Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE VIVID bimekizumab in moderate to severe plaque psoriasis phase 3 trial
Warren, Richard B.
Langley, Richard G.
Asahina, Akihiko
Augustin, Matthias
Merola, Joseph F.
Gottlieb, Alice B.
Ciaravino, Valerie
Cioffi, Christopher
Peterson, Luke
Lebwohl, Mark
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB137 - AB137
[43] Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial
Imafuku, Shinichi
Nemoto, Osamu
Okubo, Yukari
Komine, Mayumi
Schafer, Peter
Petric, Rosemary
Ohtsuki, Mamitaro
JOURNAL OF DERMATOLOGY, 2021, 48 (01): : 80 - 84
[44] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
Blauvelt, Andrew
Reich, Kristian
Drew, Janice
Peterson, Luke
Lebwohl, Mark
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
[45] Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials
Sandra Adsit
Enrique Rivas Zaldivar
Howard Sofen
Ignacio Dei-Cas
César Maldonado-García
Elkin O. Peñaranda
Luís Puig
Xiangyi Meng
Todd Fox
Adriana Guana
Advances in Therapy, 2017, 34 : 1772 - 1772
[46] Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials
Kokolakis, Georgios
Warren, Richard B.
Strober, Bruce
Blauvelt, Andrew
Puig, Luis
Morita, Akimichi
Gooderham, Melinda
Koerber, Andreas
Vanvoorden, Veerle
Wang, Maggie
de Cuyper, Dirk
Madden, Cynthia
Gomez, Natalie Nunez
Lebwohl, Mark
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) : 330 - 340
[47] Herpes virus infections amongst moderate to severe atopic dermatitis patients treated with baricitinib: an integrated analysis of phase 3 trials
Werfel, T.
Irvine, A. D.
Bangert, C.
Seneschal, J.
Grond, S.
Cardillo, T.
Brinker, D.
Zhong, J.
Riedl, E.
Wollenberg, A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S162 - S162
[48] Ixekizumab in patients with psoriasis and psoriatic arthritis: Pooled analysis of three phase 3 studies in moderate-to-severe psoriasis
Gottlieb, Alice
Papp, Kim
Duffin, Kristina Callis
Birbara, Charles
Cuchacovich, Raquel
Shuler, Catherine
Burge, Russel
Erickson, Janelle
Kerr, Lisa
Mease, Philip
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S26 - S26
[49] Incidence of cardiovascular events among tildrakizumab-treated patients with moderate to severe plaque psoriasis: Pooled data from 3 large randomized clinical trials
Bissonnette, Robert
Fernandez-Penas, Pablo
Puig, Lluis
Mendelsohn, Alan M.
Rozzo, Stephen J.
Menter, Alan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB79 - AB79
[50] Assessing real-world outcomes for patients with moderate-to-severe psoriasis who have completed clinical trials for the biologic agent bimekizumab within the Australian clinical context
Darch, Katherine
Sterne, Samuel
Supranowicz, Madeleine
Spelman, Lynda
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 29 - 29

← 1 2 3 4 5 →